| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $166,848 ) |
| | 2025 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21AR082129 | Multifactorial contribution of bone nanoscale composition to tissue quality in osteoporosis | 001 | 3 | NIH | 11/27/2024 | $63,882 |
| | 2025 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21AR082129 | Multifactorial contribution of bone nanoscale composition to tissue quality in osteoporosis | 004 | 3 | NIH | 3/5/2025 | $117,186 |
| | 2025 | 2023 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01EY029298 | Sustained Ocular Drug Delivery System for Anti-VEGF Agents | 000 | 6 | NIH | 3/7/2025 | $0 |
| | 2025 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R15GM135891 | Modular Approaches to Unusual Borylated Heterocycles using Novel Acylborons and alpha-Hydroxy borons as Enabling Tools | 000 | 1 | NIH | 4/9/2025 | -$3,537 |
| | 2025 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R15GM140421 | Membrane-Acting Peptides | 000 | 1 | NIH | 1/29/2025 | -$10,683 |
|
| Issue Date FY: 2024 ( Subtotal = $2,486,409 ) |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R35GM142953 | Multi-contrast dynamic optical imaging to advance live developmental biology | 000 | 4 | NIH | 7/19/2024 | $385,500 |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01LM011826 | BIGDATA: Causal Inference in Large-Scale Time Series | 000 | 11 | NIH | 3/20/2024 | $253,384 |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01LM011826 | BIGDATA: Causal Inference in Large-Scale Time Series | 001 | 11 | NIH | 5/10/2024 | $28,154 |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01EY032222 | Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR) | 000 | 4 | NIH | 5/17/2024 | $446,347 |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R21NS135482 | Epileptic Electrophysiological Brain Networks Modeling with Partially Observable Brain Regions | 000 | 1 | NIH | 8/9/2024 | $438,836 |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R35GM143091 | Novel Acylborons and Alpha-hydroxy Borons to Enable Modular, Regio- and Stereocontrolled Synthesis of Bioactive Molecules and Protein Conjugates | 000 | 4 | NIH | 7/24/2024 | $373,865 |
| | 2024 | 2024 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01EY036203 | Deep Learning-based Diagnosis of Retinopathy of Prematurity | 000 | 1 | NIH | 8/8/2024 | $580,331 |
| | 2024 | 2023 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R56HL113577 | Improved ventilation of the edematous lung | 000 | 10 | NIH | 5/10/2024 | $123,642 |
| | 2024 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R15HD109791 | The Patient Journey for Children with Medical Complexity during Pandemic Era andits implications. | 000 | 1 | NIH | 8/29/2024 | $0 |
| | 2024 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21CA256615 | High-Resolution Dynamic Imaging of Ovarian Cancer Metastasis Post Chemotherapy | 000 | 2 | NIH | 4/11/2024 | -$180 |
| | 2024 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R21HD104164 | Assessing Children's Screen Time with Wearable Sensor | 000 | 2 | NIH | 8/8/2024 | $0 |
| | 2024 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01LM013308 | Harnessing Patient Generated Data to Find Causes and Effects of Diet in Pregnancy | 000 | 4 | NIH | 9/12/2024 | -$191 |
| | 2024 | 2021 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21EB028409 | In vivo imaging platform for ectopic pregnancy research in mouse models | 000 | 4 | NIH | 2/15/2024 | -$12,846 |
| | 2024 | 2021 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R15GM085774 | Molecular mechanisms of metal-mediated biological functions for NO, O2, and HNO | 000 | 5 | NIH | 5/10/2024 | $0 |
| | 2024 | 2021 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01HL113577 | Improved ventilation of the edematous lung | 000 | 9 | NIH | 5/10/2024 | -$123,642 |
| | 2024 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21AG067442 | Personalized predictions of biomarker progression in Alzheimer's disease | 000 | 1 | NIH | 12/7/2023 | -$273 |
| | 2024 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R15NR018965 | Patients Perceptions of Electronic Health Record use during initial oncology outpatient clinic visits | 000 | 1 | NIH | 11/1/2023 | -$302 |
| | 2024 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | ONE CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | K22CA218462 | Transcriptional regulation of oncogenic cellular plasticity in the intestinal epithelium | 000 | 3 | NIH | 12/4/2023 | -$6,217 |
|
| Issue Date FY: 2023 ( Subtotal = $2,685,937 ) |
| | 2023 | 2023 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R35GM143091 | Novel Acylborons and Alpha-hydroxy Borons to Enable Modular, Regio- and Stereocontrolled Synthesis of Bioactive Molecules and Protein Conjugates | 000 | 3 | NIH | 6/27/2023 | $361,784 |
| | 2023 | 2023 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R35GM142953 | Multi-contrast dynamic optical imaging to advance live developmental biology | 000 | 3 | NIH | 7/24/2023 | $385,500 |
| | 2023 | 2023 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01EY029298 | Sustained Ocular Drug Delivery System for Anti-VEGF Agents | 001 | 6 | NIH | 2/13/2023 | $257,400 |
| | 2023 | 2023 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R56HL113577 | Improved ventilation of the edematous lung | 000 | 10 | NIH | 9/25/2023 | $576,525 |
| | 2023 | 2023 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01LM011826 | BIGDATA: Causal Inference in Large-Scale Time Series | 000 | 10 | NIH | 2/8/2023 | $281,538 |
| | 2023 | 2023 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01EY032222 | Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR) | 002 | 3 | NIH | 6/5/2023 | $452,262 |
| | 2023 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01EY032222 | Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR) | 001 | 2 | NIH | 5/18/2023 | $203,250 |
| | 2023 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R15HD109791 | The Patient Journey for Children with Medical Complexity during Pandemic Era andits implications. | 000 | 1 | NIH | 11/21/2022 | -$32,413 |
| | 2023 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01EY029298 | Sustained Ocular Drug Delivery System for Anti-VEGF Agents | 005 | 5 | NIH | 5/20/2023 | $87,796 |
| | 2023 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01EY029298 | Sustained Ocular Drug Delivery System for Anti-VEGF Agents | 000 | 5 | NIH | 12/1/2022 | $0 |
| | 2023 | 2022 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R21HD104164 | Assessing Children's Screen Time with Wearable Sensor | 001 | 2 | NIH | 6/22/2023 | $168,266 |
| | 2023 | 2021 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01HL113577 | Improved ventilation of the edematous lung | 001 | 9 | NIH | 9/23/2023 | $0 |
| | 2023 | 2021 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01HL113577 | Improved ventilation of the edematous lung | 000 | 9 | NIH | 6/8/2023 | $0 |
| | 2023 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R15GM135891 | Modular Approaches to Unusual Borylated Heterocycles using Novel Acylborons and alpha-Hydroxy borons as Enabling Tools | 000 | 1 | NIH | 8/4/2023 | $0 |
| | 2023 | 2020 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R15GM140421 | Membrane-Acting Peptides | 000 | 1 | NIH | 8/4/2023 | $0 |
| | 2023 | 2017 | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 1 CASTLEPOINT ON HUDSON | HOBOKEN | NJ | 07030 | HUDSON | USA | R01NR015371 | NRI: An Egocentric Computer Vision based Active Learning Co-Robot Wheelchair | 000 | 3 | NIH | 10/1/2022 | -$55,971 |
|
| Issue Date FY: 2022 ( Subtotal = $3,007,982 ) (Continued on the next page) |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21CA256615 | High-Resolution Dynamic Imaging of Ovarian Cancer Metastasis Post Chemotherapy | 000 | 2 | NIH | 11/16/2021 | $167,192 |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01EY032222 | Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR) | 001 | 2 | NIH | 9/21/2022 | $504,051 |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01LM013308 | Harnessing Patient Generated Data to Find Causes and Effects of Diet in Pregnancy | 000 | 4 | NIH | 4/20/2022 | $282,109 |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01LM011826 | BIGDATA: Causal Inference in Large-Scale Time Series | 004 | 9 | NIH | 2/22/2022 | $281,538 |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R21HD104164 | Assessing Children's Screen Time with Wearable Sensor | 001 | 2 | NIH | 9/23/2022 | $181,628 |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R15HD109791 | The Patient Journey for Children with Medical Complexity during Pandemic Era andits implications. | 000 | 1 | NIH | 9/14/2022 | $489,163 |
| | 2022 | 2022 | STEVENS INSTITUTE OF TECHNOLOGY (INC) | 1 CASTLE POINT ON HUDSON | HOBOKEN | NJ | 07030-5906 | HUDSON | USA | R01EY029298 | Sustained Ocular Drug Delivery System for Anti-VEGF Agents | 002 | 5 | NIH | 9/21/2022 | $561,278 |
|
